Preclinical Testing of Erlotinib in a Transgenic Alveolar Rhabdomyosarcoma Mouse Model

Rhabdomyosarcoma is an aggressive childhood malignancy, accounting for more than 50% of all soft-tissue sarcomas in children. Even with extensive therapy, the survival rate among alveolar rhabdomyosarcoma patients with advanced disease is only 20%. The receptor tyrosine kinase Epidermal Growth Facto...

Descripción completa

Detalles Bibliográficos
Autores principales: Abraham, Jinu, Nelon, Laura D., Kubicek, Courtney B., Kilcoyne, Aoife, Hampton, Sheila T., Zarzabal, Lee Ann, Giles, Francis J., Michalek, Joel E., Rubin, Brian P., Keller, Charles
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087964/
https://www.ncbi.nlm.nih.gov/pubmed/21559212
http://dx.doi.org/10.1155/2011/130484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087964/
https://www.ncbi.nlm.nih.gov/pubmed/21559212
http://dx.doi.org/10.1155/2011/130484

Ejemplares similares